Literature DB >> 4387222

Cephalexin and cephaloglycin activity in vitro and absorption and urinary excretion of single oral doses in normal young adults.

P Braun, J R Tillotson, C Wilcox, M Finland.   

Abstract

A large number of recently isolated bacterial pathogens were tested for susceptibility to cephalexin and cephaloglycin by the replica inoculating method. Strains of group A hemolytic streptococci, viridans (alpha and gamma) streptococci, pneumococci, gonococci, meningococci, and penicillin G-sensitive Staphylococcus aureus were all moderately to highly susceptible to both of these cephalosporin analogues, nearly all of the strains being two to eight (median four) times more susceptible to cephaloglycin than to cephalexin. The penicillin G-resistant, penicillinase-producing strains of S. aureus varied in their susceptibility; many were moderately resistant to both analogues, particularly to cephalexin. Strains of enterococci, Haemophilus influenzae, and most of the common gram-negative bacilli were moderately to highly resistant. Reducing the size of the inoculum had variable effects on inhibition by these drugs, depending on the species or strain. The activity of cephalexin was very little affected by pH of the medium within the clinical range or by incubation at 37 C in broth for up to 24 hr. In contrast, cephaloglycin in broth deteriorated rapidly at 37 C, and its activity was markedly reduced in alkaline medium. Both cephalexin and cephaloglycin were rapidly absorbed and excreted into the urine after single oral doses of 500 mg. Much higher levels were achieved and sustained with the former. Absorption of both analogues was delayed when taken with food, and the levels in the serum were significantly higher and better sustained when probenecid was also given. Very high concentrations of cephalexin were excreted into the urine during the first 4 hr, and the levels were still high in the 4- to 8-hr collection. The concentrations of cephaloglycin in the urine at these times were much lower. An average of 80 to 93% of the dose of cephalexin and 25 to 30% of the cephaloglycin were accounted for as active drug in the urine collected in 8 hr. Both analogues were well tolerated.

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 4387222      PMCID: PMC547740          DOI: 10.1128/am.16.11.1684-1694.1968

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  14 in total

1.  Comparative studies of ampicillin, cephalothin and a new cephalosporin derivative, cephaloglycin.

Authors:  C M Kunin; D Brandt
Journal:  Am J Med Sci       Date:  1968-03       Impact factor: 2.378

2.  Resistance and cross-resistance of Staphylococcus aureus, Escherichia coli, and Aerobacter species to cephalosporins and semisynthetic penicillins.

Authors:  J L Ott; C W Godzeski
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1966

3.  Clinical evaluation of cephaloridine.

Authors:  N H Steigbigel; J W Kislak; J G Tilles; M Finland
Journal:  Arch Intern Med       Date:  1968-01

4.  Cephaloridine activity in vitro and absorption and urinary excretion in normal young men.

Authors:  J W Kislak; B W Steinhauer; M Finland
Journal:  Am J Med Sci       Date:  1966-04       Impact factor: 2.378

5.  Clinical experience with cephaloglycin.

Authors:  L B Hogan; W J Holloway; R A Jakubowitch
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1967

6.  Levels of penicillin in serum of newborn infants.

Authors:  M Abramowicz; J O Klein; D Ingall; M Finland
Journal:  Am J Dis Child       Date:  1966-03

7.  In vitro antimicrobial activity and human pharmacology of cephaloglycin.

Authors:  J M Applestein; E B Crosby; W D Johnson; D Kaye
Journal:  Appl Microbiol       Date:  1968-07

8.  Cephalexin, a new orally absorbed cephalosporin antibiotic.

Authors:  W E Wick
Journal:  Appl Microbiol       Date:  1967-07

9.  Factors influencing in vitro susceptibility to the cephalosporins and clinical trial of an oral cephalosporin, cephaloglycin.

Authors:  A R Ronald; M Turck
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1966

10.  Laboratory and clinical studies of a new antibiotic, cephaloglycin in the treatment of urinary tract infections.

Authors:  J L Boyer; V T Andriole
Journal:  Yale J Biol Med       Date:  1968-02
View more
  10 in total

1.  Susceptibility of beta-hemolytic streptococci to 65 antibacterial agents.

Authors:  M Finland; C Garner; C Wilcox; L D Sabath
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

Review 2.  Cephalexin: a review of its antibacterial, pharmacological and therapeutic properties.

Authors:  T M Speight; R N Brogden; G S Avery
Journal:  Drugs       Date:  1972       Impact factor: 9.546

Review 3.  Infectious diseases: annual review of significant publications.

Authors:  H A Reimann
Journal:  Postgrad Med J       Date:  1970-05       Impact factor: 2.401

Review 4.  Cephalexin--a new oral antibiotic.

Authors:  A Bailey; A Walker; A Hadley; D G James
Journal:  Postgrad Med J       Date:  1970-03       Impact factor: 2.401

5.  A method for studying antibiotic concentrations in inflammatory exudate.

Authors:  J A Raeburn
Journal:  J Clin Pathol       Date:  1971-10       Impact factor: 3.411

Review 6.  Cephalosporin-probenecid drug interactions.

Authors:  G R Brown
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

7.  Regression curve analysis of cephalosporin activity.

Authors:  J A Washington; P K Yu
Journal:  Appl Microbiol       Date:  1970-04

8.  Sensitivity of Haemophilus influenzae to antibiotics.

Authors:  J D Williams; J Andrews
Journal:  Br Med J       Date:  1974-01-26

9.  Diabetes downregulates peptide transporter 1 in the rat jejunum: possible involvement of cholate-induced FXR activation.

Authors:  Li-Min Liang; Jun-Jie Zhou; Feng Xu; Pei-Hua Liu; Lan Qin; Li Liu; Xiao-Dong Liu
Journal:  Acta Pharmacol Sin       Date:  2020-04-27       Impact factor: 7.169

10.  In vitro susceptibility of selected bacteria to cefaclor.

Authors:  A J Valenti; V T Andriole
Journal:  Yale J Biol Med       Date:  1977 Sep-Oct
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.